Medicare for All without tackling the extreme consolidation in health care would just funnel money to corporate behemoths, a new report states.
prescription drugs
Posted inPolitics
Does Xavier Becerra Know What a PBM Is?
The question speaks to how in the Democratic Party, there is no price paid for the inability to govern.
Posted inHealth and Social Policy
The Mifepristone Wars—and What They Mean for Black Women
Still concentrated in Southern states that ban abortion, Black women disproportionately rely on telehealth, which the Supreme Court has allowed—provisionally—to continue.
Posted inLaw and Justice
History Teaches: Reproductive Rights and Equality
A court in Pennsylvania gets it right, and the Fifth Circuit gets it wrong.
Posted inTAP
The Mifepristone Ruling Revives Pro-Choice Politics
A federal court’s ban on the mailing of abortion medication once again demonstrates the unpopularity of anti-abortion zealotry.
Posted inEconomic Policy
When in Doubt, Pretend to Be Lina Khan
The Trump administration’s plans to lower prices are just Biden-era retreads. Unfortunately, they’re just plans, with no expected follow-through.
Posted inHealth and Social Policy
Republicans Scramble for Health Care Ideas as Obamacare Deadline Looms
Next week, massive premium increases get locked in. The GOP has shown no interest in stopping it, or preventing any other increases in health care costs.
Posted inEconomic Policy
Meet the Connectors
Middlemen, our economy’s most shadowy characters, sit in between buyers and sellers and get rich in the process. It can even be a matter of life or death.
Posted inHealth and Social Policy
‘TrumpRx’ Is Another Pretend Solution for High Drug Prices
The proposed government website will just refer people to the drug companies, which use direct-to-consumer pricing to distract from continued high profits.
Posted inHealth and Social Policy
Trump’s Order to Cut Drug Prices Would Raise Drug Prices
The so-called ‘pill penalty’ fix is a corporate favor designed to increase the period where prescriptions are immune from price negotiations.